Table 1.
Hemisphere | Lesion | Treatment | DA | DOPAC | NE | 5-HT | 5-HIAA |
---|---|---|---|---|---|---|---|
Ipsilateral | Sham | Vehicle | 33 ± 2 | 43 ± 3 | 279 ± 22 | 327 ± 11 | 3513 ± 234 |
Contralateral | -- | 35 ± 3 | 48 ± 4 | 305 ± 12 | 258 ± 13 | 3551 ± 199 | |
Ipsilateral | 6-OHDA | Vehicle | 29 ± 5 | 32 ± 7 | * 126 ± 50 | 291 ± 25 | 3679 ± 289 |
Contralateral | -- | 33 ± 2 | 52 ± 9 | 343 ± 13 | 346 ± 79 | 4212 ± 292 | |
Ipsilateral | Sham | L-DOPA (6 mg/kg) |
* 94 ± 9 | * 85 ± 10 | 243 ± 14 | 239 ± 22 | 3187 ± 135 |
Contralateral | -- | 88 ± 4 | 83 ± 2 | 270 ± 5 | 240 ± 16 | 3484 ± 177 | |
Ipsilateral | 6-OHDA | L-DOPA (6 mg/kg) |
# § 66 ± 5 | # 54 ± 5 | § 36 ± 18 | 664 ± 305 | 3651 ± 146 |
Contralateral | -- | 76 ± 6 | 99 ± 16 | 284 ± 20 | 231 ± 20 | 3846 ± 242 |
Rats received unilateral injections of 6-hydroxydopamine (6-OHDA) or sham into the medial forebrain bundle (n = 7 per group). After recovery, rats were treated with daily L-DOPA 6 mg/kg or vehicle (Veh) and decapitated 60 min after final injection. Primary motor cortex tissue was processed via high performance liquid chromatography for concentrations of dopamine (DA), the DA metabolite 3,4-dihydroxyphenylacetic acid (DOPAC), norepinephrine (NE), serotonin (5-HT) or the 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA). Reported values are mean pg (of monoamine) per mg (of tissue) ± SEM. Individual planned contrasts were only performed on the ipsilateral hemisphere.
p < .05 vs. Sham + Veh;
p < .05 vs. 6-OHDA + Veh;
p < .05 vs. Sham + L-DOPA.